Skip to Content

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

Many patients with advanced-stage lung cancer cannot tolerate standard platinum-based chemotherapy. As a late-breaking Siow Ming Lee presents the first randomized trial to show that first-line atezolizumab treatment significantly improves overall survival compared to single agent chemotherapy for these poor prognosis patients with no EGFR and ALK alterations.

Siow Ming Lee

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top